Federal regulators have cleared a test that estimates one of cardiology's most useful numbers without threading a catheter into the heart.
The FDA cleared the CorVista System with a Pulmonary Capillary Wedge Pressure add-on, announced Tuesday by CorVista Health and Analytics For Life. The add-on uses a machine-learned algorithm to analyze electrical and hemodynamic signals collected over a few minutes of rest, and indicates the likelihood that a patient has elevated wedge pressure.
The number matters because it is central to diagnosing heart failure with preserved ejection fraction, a form of the disease in which the heart pumps normally by the usual measure but fills poorly. HFpEF accounts for roughly half of heart failure cases, and it is routinely missed.
Two words in that description carry the weight of the story. The test estimates a likelihood. It does not measure a pressure.
What Wedge Pressure Actually Tells a Cardiologist
Pulmonary capillary wedge pressure is an indirect read on the pressure inside the left atrium and the filling pressure of the left ventricle. When it is elevated, blood is backing up behind a stiff left ventricle that cannot relax and fill properly, which is the mechanical signature of HFpEF.
Getting that number today usually requires right heart catheterization. A catheter is threaded through a vein, into the right side of the heart, and out into the pulmonary artery, where a small balloon is inflated to briefly wedge the catheter and record the pressure downstream.
It is a routine procedure in experienced hands, and it remains the reference standard. It is also invasive, requires a catheterization lab and a trained operator, carries a small risk of bleeding, arrhythmia, and vessel injury, and costs enough that it is not ordered casually. Many patients with unexplained shortness of breath never get one, which is a large part of why HFpEF goes unrecognized.
The cleared test is intended for patients with cardiovascular symptoms such as chest pain, shortness of breath, and fatigue who have no history of elevated wedge pressure and have not had a prior right heart catheterization. In other words, it is aimed at the front of the diagnostic pathway rather than at replacing the catheter for patients already deep into a workup.
What Clearance Establishes and What It Does Not
This distinction is where health coverage of new devices most often goes wrong, so it is worth being precise.
FDA clearance is not FDA approval. Approval, the higher bar, generally requires evidence that a device is safe and effective on its own terms. Clearance generally rests on a demonstration that a device is substantially equivalent to one already legally marketed, and it does not require proof that the new device performs better than an existing option.
Applied here, clearance means the FDA permitted the test to be marketed for the stated use. It does not mean the algorithm has been shown to match right heart catheterization, and it does not establish that using the test improves patient outcomes. Those are different questions that clearance does not answer.
The company reported in August of last year that a clinical study of the algorithm met its primary sensitivity endpoint. Sensitivity is the measure that matters most for a screening-style tool, since the point is to avoid missing people who have the condition. Sensitivity alone does not describe how many people without elevated pressure the test will incorrectly flag, and that false-positive rate determines how many unnecessary downstream tests a tool generates.
The specific performance numbers and the regulatory pathway will be posted in the FDA's public clearance database, and clinicians evaluating the test should read them there rather than relying on announcement language.
MedicalDaily covered a similar clearance in June, when the FDA cleared an AI tool that reads routine ECGs to flag hidden structural heart disease. The two products address different problems. That one looks for structural abnormalities. This one estimates a pressure.
Why This Form of Heart Failure Is So Often Missed
Heart failure affects roughly 7.7 million Americans. The version most people picture, with a weakened pump and a low ejection fraction, is the one echocardiography catches readily.
HFpEF is harder. The ejection fraction looks normal, so a standard echocardiogram can come back reassuring while the patient continues to struggle. Symptoms are non-specific and overlap heavily with obesity, deconditioning, anemia, lung disease and anxiety. Patients are frequently told to lose weight or manage stress, sometimes for years, before anyone measures a filling pressure.
The population most affected skews older and female, and carries a heavy load of hypertension, obesity, diabetes, atrial fibrillation and kidney disease. It is also a population for whom access to a catheterization lab is uneven. Rural patients, patients without a nearby cardiology practice, and patients whose insurance makes specialist referral difficult are the least likely to reach the test that would give them an answer.
That access gap is the real argument for a point-of-care alternative, and it is the claim worth watching. CorVista president and chief executive Adrian Lam said that for people with suspected heart failure "the path to a clear answer is still too long." The company also states the platform now supports assessment across conditions accounting for up to 75 percent of people with symptomatic cardiovascular disease, a figure that comes from the manufacturer rather than an independent evaluation.
What Patients Should Take From This
Nothing changes this week for anyone currently being evaluated for heart failure. A cleared device is not the same as an available one, and availability depends on which health systems buy it, which clinicians adopt it, and whether insurers pay.
That last question is unsettled. The American Medical Association granted a Category III procedure code covering this type of AI cardiopulmonary analysis at the start of July. Category III codes are for emerging technology and are used to track use. They do not obligate any payer to reimburse, and coverage decisions typically follow later, if at all.
Patients with unexplained shortness of breath, fatigue, or exercise intolerance should still pursue evaluation through the normal route rather than waiting for a new test to appear locally. A reasonable conversation with a clinician covers whether an echocardiogram, natriuretic peptide blood testing, or cardiology referral is warranted. Anyone with chest pain, severe breathlessness, fainting, or swelling that worsens rapidly needs urgent care, not a diagnostic debate.
Nobody should change or stop a cardiac medication based on a news report about a diagnostic device.
What Happens Next
The FDA clearance record will publish the device's performance data. Real-world validation, meaning studies showing the test performs in community practice as it did in the clinical dataset, is the evidence that would justify wider adoption, and it does not exist yet. Payer coverage decisions are the practical gate.
MedicalDaily will report on the published performance figures, on independent validation, and on any coverage determination.
The confirmed fact is that the FDA cleared a non-invasive test that indicates the likelihood of elevated pulmonary capillary wedge pressure in symptomatic patients. The people most affected are those with suspected HFpEF, particularly where catheterization is hard to reach. The most reasonable action is to pursue standard evaluation for unexplained breathlessness now. The central uncertainty is how accurate the estimate proves to be outside the study setting, and whether insurers will pay for it.
Frequently Asked Questions
What did the FDA clear? An add-on to the CorVista System that uses a machine-learned algorithm to indicate the likelihood of elevated pulmonary capillary wedge pressure without a catheter.
What is pulmonary capillary wedge pressure? An indirect measure of pressure in the left atrium and the filling pressure of the left ventricle. Elevated readings point toward heart failure with preserved ejection fraction.
Does this replace a heart catheterization? No. Right heart catheterization remains the reference standard. The cleared test estimates a likelihood and is aimed at patients who have not had a catheterization.
Is FDA clearance the same as FDA approval? No. Clearance generally rests on substantial equivalence to a device already on the market and does not require proof that the new device is better.
Why is HFpEF hard to diagnose? Ejection fraction looks normal on a standard echocardiogram, and symptoms overlap with obesity, deconditioning, lung disease and anemia.
Will my insurance cover it? Unclear. A Category III procedure code exists for this type of analysis, but such codes track emerging technology and do not require any payer to reimburse.
What should I do if I have unexplained shortness of breath? See a clinician. Standard evaluation may include an echocardiogram, blood testing and cardiology referral. Seek urgent care for chest pain, fainting, or rapidly worsening swelling.
